Piper Jaffray Companies reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Monday, December 16th, Stock Target Advisor reports. Piper Jaffray Companies currently has a $104.00 price target on the stock.
Other equities analysts have also recently issued reports about the company. TheStreet raised Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a report on Monday, November 25th. Chardan Capital reissued a buy rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a report on Monday, September 30th. Finally, BidaskClub cut Crispr Therapeutics from a strong-buy rating to a buy rating in a report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of Buy and an average target price of $71.38.
Shares of Crispr Therapeutics stock traded down $2.00 during trading on Monday, reaching $59.90. The company’s stock had a trading volume of 1,291,641 shares, compared to its average volume of 1,282,267. The business has a 50 day moving average price of $65.94 and a 200-day moving average price of $51.65. The company has a market capitalization of $3.45 billion, a P/E ratio of -17.41 and a beta of 3.20. Crispr Therapeutics has a 12-month low of $29.34 and a 12-month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. BSW Wealth Partners acquired a new position in shares of Crispr Therapeutics in the second quarter worth about $39,000. Balyasny Asset Management LLC acquired a new stake in Crispr Therapeutics during the second quarter valued at approximately $5,165,000. Millennium Management LLC acquired a new stake in Crispr Therapeutics during the third quarter valued at approximately $4,366,000. BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics during the second quarter valued at approximately $41,000. Finally, Bank of New York Mellon Corp raised its stake in Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after buying an additional 17,810 shares in the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What does an equal weight rating mean?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.